Close
Back to MNKD Stock Lookup
Pages: 1 2 3 4 5 6 »» Last Page

MannKind (MNKD) – Company Press Releases

Apr 3, 2024 06:00 AM MannKind Repays Certain Debt Obligations
Mar 26, 2024 04:05 PM MannKind Announces CFO Transition
Mar 11, 2024 06:05 AM INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
Mar 5, 2024 06:05 AM MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
Mar 4, 2024 01:01 PM MannKind Corporation Announces Participation at Upcoming Conferences
Feb 27, 2024 04:00 PM MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
Feb 20, 2024 06:00 AM MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
Feb 15, 2024 06:05 AM MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
Jan 2, 2024 06:05 AM MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
Dec 28, 2023 06:00 AM MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
Nov 7, 2023 04:00 PM MannKind Corporation Reports 2023 Third Quarter Financial Results
Nov 6, 2023 06:15 AM MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
Oct 31, 2023 04:00 PM MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
Oct 30, 2023 06:15 AM MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
Sep 5, 2023 06:00 AM MannKind Corporation Announces Participation at Upcoming Conferences
Aug 7, 2023 04:00 PM MannKind Corporation Reports 2023 Second Quarter Financial Results
Aug 1, 2023 06:00 AM MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
Jul 31, 2023 04:00 PM MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
Jun 22, 2023 06:05 AM MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
Jun 11, 2023 08:05 AM Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone
May 24, 2023 08:30 AM Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
May 10, 2023 06:00 AM MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
May 9, 2023 08:21 PM CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results
May 9, 2023 04:00 PM Mannkind Corporation Reports 2023 First Quarter Financial Results
May 2, 2023 05:00 PM MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
May 2, 2023 05:00 PM MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
Mar 27, 2023 04:05 PM Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
Mar 7, 2023 05:00 PM MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
Mar 7, 2023 05:00 PM MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
Feb 23, 2023 04:00 PM MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
Feb 23, 2023 04:00 PM MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
Feb 22, 2023 06:05 AM MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
Feb 16, 2023 05:00 PM MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
Feb 16, 2023 05:00 PM MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
Feb 10, 2023 05:00 PM Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
Feb 10, 2023 05:00 PM Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
Jan 24, 2023 06:00 AM MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
Jan 24, 2023 06:00 AM MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
Jan 23, 2023 06:05 AM MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
Jan 5, 2023 06:00 AM MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
Jan 5, 2023 06:00 AM MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
Nov 10, 2022 06:05 AM MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
Nov 8, 2022 08:00 AM MannKind Corporation Reports 2022 Third Quarter Financial Results
Nov 8, 2022 08:00 AM MannKind Corporation Reports 2022 Third Quarter Financial Results
Nov 1, 2022 06:00 AM MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
Nov 1, 2022 06:00 AM MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
Sep 21, 2022 05:00 PM MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
Sep 21, 2022 05:00 PM MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
Sep 6, 2022 06:15 AM Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
Sep 6, 2022 06:15 AM Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
Pages: 1 2 3 4 5 6 »» Last Page

Back to MNKD Stock Lookup